Skip to content
Awesome – Lifestyle
Author:
GlycoEra
GlycoEra Initiates Phase 1a Trial of GE8820, the First IgG4-Selective Degrader to Enter the Clinic
November 16, 2026
GlycoEra Appoints Andrea Matthews as Chief Business Officer to Support Next Phase of Company Growth
September 16, 2026